Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II nab-paclitaxel + gemcitabine first-line trial in advanced or metastatic cholangiocarcinoma
2015-002066-24Phase 2Completed
- Sponsor
- Cancer Trials Ireland
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and gemcitabine in cholangiocarcinoma (CCA), sponsored by Cancer Trials Ireland. Primary endpoint: Progression-free survival at 6 months. Started Jul 2015; status: completed.
02
Drugs
paclitaxelgemcitabine
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2015-002066-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002066-24.